We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Indocyangreen Elimination in Cirrhosis and Acute Liver Failure

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00245310
First Posted: October 27, 2005
Last Update Posted: October 11, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Heidelberg University
  Purpose

Indocyangreen (ICG)is totally biliary eliminated and corresponds to hepatocyte function and liver perfusion.

The ICG-clearance will be evaluated as a prognostic marker in liver disease.


Condition Intervention
Acute Liver Failure Liver Cirrhosis Procedure: Indocyangreen (ICG) clearance

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure

Resource links provided by NLM:


Further study details as provided by Heidelberg University:

Estimated Enrollment: 40
Study Start Date: October 2005
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Detailed Description:
patients with acute liver failure or advanced liver disease will be studied. ICG-clearance will be correlated with established clinical scores and outcome.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Criteria

Inclusion Criteria:

  • acute liver failure OR end-stage liver disease
  • normal hepatic perfusion by doppler ultrasound

Exclusion Criteria:

  • portal vein thrombosis
  • allergy to ICG or iodine
  • thyroid disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245310


Locations
Germany
University of Heidelberg
Heidelberg, Germany, 69120
Sponsors and Collaborators
Heidelberg University
Investigators
Principal Investigator: Jens Encke, PD Dr. med. Heidelberg University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00245310     History of Changes
Other Study ID Numbers: LiMON
First Submitted: October 25, 2005
First Posted: October 27, 2005
Last Update Posted: October 11, 2010
Last Verified: November 2008

Keywords provided by Heidelberg University:
ICG clearance
liver cirrhosis
acute liver failure
prognosis

Additional relevant MeSH terms:
Fibrosis
Liver Cirrhosis
Liver Failure
Liver Failure, Acute
Pathologic Processes
Liver Diseases
Digestive System Diseases
Hepatic Insufficiency